20-quarter listed-company comparison

Drug Manufacturers - General Stocks

Drug Manufacturers - General: Johnson & Johnson owns the largest revenue base; Eli Lilly and Company has the fastest current growth.

01 · the industry itself · before any single company

How has Drug Manufacturers - General moved against S&P 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this industry is 23% behind S&P 500. Earnings across its companies grew 31% on average over the last four reported quarters.

FADING · −1 in 4w~Fundamentals up, price down8 of 17 companies ahead of S&P 500 by 5% or more over three months1 is 20% or more behind over a year while earnings grew 20% or more

RS ↑1w · 10/17 >200d (−3) · 8/17 lead (−1) · EPS 9/17↑

Drug Manufacturers - General, equal-weighted, based at 200 S&P 500, same base, same start trailing 12-month earnings per share rising falling

Both lines start at 200 in the same week, so the distance between them is the whole story: the industry line is an equal-weighted index of its 17 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the industry taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

02 · sector relative strength, before individual stocks

Is Drug Manufacturers - General outperforming S&P 500?

Drug Manufacturers - General has outperformed S&P 500 by 8% over the last 52 weeks. Over 13 weeks the gap is a lead of 5.4%. 9 of 16 covered companies currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. Organon & Co. is the strongest against the sector itself at +25.7%.

+5.4%Sector vs S&P 500 · 13 weeks

+8.0%Sector vs S&P 500 · 52 weeks

9/16Stocks leading S&P 500

9/16Stocks leading sector

Sector metric: — as of latest available · unclassified · direction unavailable.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

Drug Manufacturers - General has outperformed S&P 500 by 8% over 52 weeks and 5.4% over 13 weeks. 9 of 16 covered companies beat the S&P 500 on Mansfield relative strength, while 9 of 16 beat the sector itself. Johnson & Johnson leads with revenue of $97,929 million, based on 15 of 16 comparable companies through Jun 2026.

Companies

complete canonical membership

Combined market value

$3.9T

Eli Lilly and Company

Revenue growing

13/15

positive TTM year-on-year growth

Beating S&P 500

9/16

positive Mansfield relative strength

Comparing 5 of 16

03 · research priority, made explicit

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%

AbbVie Inc. has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 75.3% evidence confidence.

Organon & Co. looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.

Gilead Sciences, Inc. has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.

How this score is built, and what the marks mean

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

Company	Score	Price stage	Growth & earnings/35	Capital efficiency/25	Valuation/20	Relative strength/20
1AbbVie Inc.ABBV	75.2/100Favorable setup75% evidence	LEADER	28.8/35 Revenue 10.4% · PAT 68.4% · OPM change 2.5 pp 95% evidence	20.1/25 ROCE 24.5% · OPM 40% 76% evidence	8.7/20 P/E 70.9× · PEG — 15% evidence	17.6/20 RS sector 6.6% · RS bench 7.2% · 1Y 18%12 of 12 weeks ahead 100% evidence
Exact sum: 28.8 + 20.1 + 8.7 + 17.6 = 75.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Bristol-Myers Squibb CompanyBMY	69.4/100Favorable setup85% evidence	BREAKING OUT	26.0/35 Revenue 3.1% · PAT 83.1% · OPM change 12.5 pp 95% evidence	12.5/25 ROCE 5.9% · OPM 31% 76% evidence	14.8/20 P/E 12.7× · PEG 0.51 65% evidence	16.1/20 RS sector 5.4% · RS bench 5.7% · 1Y 41.3%8 of 12 weeks ahead 100% evidence
Exact sum: 26 + 12.5 + 14.8 + 16.1 = 69.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Eli Lilly and CompanyLLY	67.1/100Favorable setup85% evidence	FADING	32.3/35 Revenue 49.6% · PAT 93.6% · OPM change 9.1 pp 95% evidence	21.3/25 ROCE 41.7% · OPM 54.2% 76% evidence	3.9/20 P/E 40× · PEG 8.59 65% evidence	9.6/20 RS sector 2.7% · RS bench 3.2% · 1Y 51.3%8 of 12 weeks ahead 100% evidence
Exact sum: 32.3 + 21.3 + 3.9 + 9.6 = 67.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
4Amgen Inc.AMGN	67.0/100Favorable setup85% evidence	BREAKING OUT	26.5/35 Revenue 9.1% · PAT 32.1% · OPM change 2.9 pp 95% evidence	16.9/25 ROCE 18.2% · OPM 35.5% 76% evidence	13.1/20 P/E 22.4× · PEG 0.71 65% evidence	10.5/20 RS sector 0.3% · RS bench 0.7% · 1Y 31.9%8 of 12 weeks ahead 100% evidence
Exact sum: 26.5 + 16.9 + 13.1 + 10.5 = 67 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Johnson & JohnsonJNJ	65.5/100Favorable setup75% evidence	BREAKING OUT	22.1/35 Revenue 8.1% · PAT -7.2% · OPM change 0.9 pp 95% evidence	16.8/25 ROCE 18.6% · OPM 29.2% 76% evidence	9.5/20 P/E 29.1× · PEG — 15% evidence	17.1/20 RS sector 8.7% · RS bench 9.1% · 1Y 51.7%9 of 12 weeks ahead 100% evidence
Exact sum: 22.1 + 16.8 + 9.5 + 17.1 = 65.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Gilead Sciences, Inc.GILD	59.9/100Mixed-positive evidence75% evidence	BREAKING OUT	14.9/35 Revenue 5.5% · PAT -151.3% · OPM change -5.5 pp 95% evidence	19.1/25 ROCE 30.9% · OPM 33.7% 76% evidence	10.5/20 P/E 18.8× · PEG — 15% evidence	15.4/20 RS sector 4.1% · RS bench 4.4% · 1Y 29.4%5 of 12 weeks ahead 100% evidence
Exact sum: 14.9 + 19.1 + 10.5 + 15.4 = 59.9 · Decision use: Price leads the evidence: RS versus the benchmark is 4.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
7Organon & Co.OGN	54.0/100Mixed-positive evidence81% evidence	TURNING	12.1/35 Revenue -2.1% · PAT -67.2% · OPM change 0.7 pp 83% evidence	10.8/25 ROCE 2.2% · OPM 16.1% 76% evidence	16.5/20 P/E 6.4× · PEG 0.17 65% evidence	14.6/20 RS sector 25.7% · RS bench 26.7% · 1Y 30.8%4 of 12 weeks ahead 100% evidence
Exact sum: 12.1 + 10.8 + 16.5 + 14.6 = 54 · Decision use: Price leads the evidence: RS versus the benchmark is 26.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
8Merck & Co., Inc.MRK	45.5/100Mixed-negative evidence85% evidence	BREAKING OUT	4.5/35 Revenue 4.6% · PAT -80.7% · OPM change -37.7 pp 95% evidence	12.3/25 ROCE 18.3% · OPM -0.2% 76% evidence	9.6/20 P/E 14.3× · PEG 1.75 65% evidence	19.1/20 RS sector 18.2% · RS bench 18.5% · 1Y 77.8%9 of 12 weeks ahead 100% evidence
Exact sum: 4.5 + 12.3 + 9.6 + 19.1 = 45.5 · Decision use: Price leads the evidence: RS versus the benchmark is 18.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
9AstraZeneca PLCAZN	44.7/100Mixed-negative evidence85% evidence	BASING	18.5/35 Revenue 8.6% · PAT 25.9% · OPM change -0.8 pp 95% evidence	14.4/25 ROCE 17.7% · OPM 23.5% 76% evidence	10.9/20 P/E 27.8× · PEG 1.08 65% evidence	0.9/20 RS sector -16% · RS bench -15.6% · 1Y 5.5%0 of 12 weeks ahead 100% evidence
Exact sum: 18.5 + 14.4 + 10.9 + 0.9 = 44.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10GSK plcGSK	43.6/100Mixed-negative evidence85% evidence	ASLEEP	15.3/35 Revenue 5% · PAT 32.1% · OPM change -19.6 pp 95% evidence	9.4/25 ROCE 1.2% · OPM 5.7% 76% evidence	14.8/20 P/E 16.8× · PEG 0.4 65% evidence	4.1/20 RS sector -8% · RS bench -7.7% · 1Y 23.7%0 of 12 weeks ahead 100% evidence
Exact sum: 15.3 + 9.4 + 14.8 + 4.1 = 43.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
11Novartis AGNVS	41.2/100Mixed-negative evidence85% evidence	ASLEEP	12.5/35 Revenue 2.7% · PAT -6.5% · OPM change 0.8 pp 95% evidence	19.3/25 ROCE 19.6% · OPM 34.6% 76% evidence	7.0/20 P/E 22.5× · PEG 2.3 65% evidence	2.4/20 RS sector -11.4% · RS bench -11.1% · 1Y 12.8%0 of 12 weeks ahead 100% evidence
Exact sum: 12.5 + 19.3 + 7 + 2.4 = 41.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Biogen Inc.BIIB	40.2/100Mixed-negative evidence85% evidence	LEADER	6.3/35 Revenue 0.3% · PAT -45.4% · OPM change -24.9 pp 95% evidence	6.1/25 ROCE 0.6% · OPM 5.6% 76% evidence	13.7/20 P/E 38.2× · PEG 0.38 65% evidence	14.1/20 RS sector 8.4% · RS bench 8.9% · 1Y 51.6%8 of 12 weeks ahead 100% evidence
Exact sum: 6.3 + 6.1 + 13.7 + 14.1 = 40.2 · Decision use: Price leads the evidence: RS versus the benchmark is 8.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
13Grifols, S.A.GRFS	40.1/100Thin evidence · provisional58% evidence	BASING	16.1/35 Revenue — · PAT — · OPM change -0.3 pp 45% evidence	8.1/25 ROCE 1.8% · OPM 14.8% 76% evidence	11.3/20 P/E 7.5× · PEG — 15% evidence	4.6/20 RS sector -18.5% · RS bench -18% · 1Y -24%0 of 12 weeks ahead 100% evidence
Exact sum: 16.1 + 8.1 + 11.3 + 4.6 = 40.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14SanofiSNY	38.3/100Mixed-negative evidence85% evidence	ASLEEP	12.5/35 Revenue 7% · PAT -32.6% · OPM change -5.2 pp 95% evidence	7.7/25 ROCE 1.1% · OPM 8.5% 76% evidence	13.1/20 P/E 22.9× · PEG 0.58 65% evidence	5.0/20 RS sector -14.8% · RS bench -14.3% · 1Y -10.6%0 of 12 weeks ahead 100% evidence
Exact sum: 12.5 + 7.7 + 13.1 + 5 = 38.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
15Amarin Corporation plcAMRN	33.6/100Thin evidence · provisional58% evidence	ASLEEP	17.9/35 Revenue 1.9% · PAT — · OPM change 14.8 pp 62% evidence	3.0/25 ROCE -2.4% · OPM -25.1% 76% evidence	8.5/20 P/E 168.5× · PEG — 15% evidence	4.2/20 RS sector -15.4% · RS bench -14.8% · 1Y -9.8%0 of 12 weeks ahead 70% evidence
Exact sum: 17.9 + 3 + 8.5 + 4.2 = 33.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Pfizer Inc.PFE	30.0/100Adverse evidence75% evidence	BREAKING OUT	5.6/35 Revenue -0.2% · PAT -59.4% · OPM change -25.1 pp 95% evidence	5.0/25 ROCE -0.4% · OPM -4.3% 76% evidence	9.3/20 P/E 32× · PEG — 15% evidence	10.1/20 RS sector -1.9% · RS bench -1.4% · 1Y 14.3%3 of 12 weeks ahead 100% evidence
Exact sum: 5.6 + 5 + 9.3 + 10.1 = 30 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

Showing 10 of 16 companies

04 · what price has already done

Market action

Merck & Co., Inc. has the strongest one-year price move in Drug Manufacturers - General at +77.8%. Organon & Co. leads on Mansfield relative strength against the S&P 500 at +26.7%. 9 of 16 covered companies are above zero on that measure. Every line covers 314 weekly closes through 2026-09-16.

Price and relative strength

Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

05 · compare level, then change

Revenue Scale & Growth Durability

Johnson & Johnson has the highest Revenue among the 16 Drug Manufacturers - General companies compared here, at $97,929 million. Eli Lilly and Company is next at $79,666 million. Eli Lilly and Company has the highest Revenue growth at 49.6%, so level and change sit with different companies. Its Revenue series carries 18 reported observations across the 20-quarter window.

What the numbers say: Johnson & Johnson is the scale leader at $97,929 million, 22.9% ahead of Eli Lilly and Company. Eli Lilly and Company's growth is 49.6% from a $79,666 million base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderJohnson & Johnson · $97,929 million

Gap22.9% versus #2 · Eli Lilly and Company

Persistence8/8 recent comparable periods

Coverage15/16 companies · 312 observations

Investor read: Johnson & Johnson is the scale benchmark; Eli Lilly and Company is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Johnson & Johnson's growth falls below Eli Lilly and Company's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenuelargest

1Johnson & Johnson JNJ$97.9B

2Eli Lilly and Company LLY$79.7B

3Merck & Co., Inc. MRK$66.6B

4AbbVie Inc. ABBV$64.4B

5Pfizer Inc. PFE$63.7B

Revenue growthfastest growers

1Eli Lilly and Company LLY50%

2AbbVie Inc. ABBV10%

3Amgen Inc. AMGN9.1%

4AstraZeneca PLC AZN8.6%

5Johnson & Johnson JNJ8.1%

Revenue · company comparison

15/16 level · 15/16 change

On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	Revenue	Revenue growth	Reported
Johnson & Johnson JNJ	$25.3B	6.6%	Jun 2026
Eli Lilly and Company LLY	$23.0B	48%	Jun 2026
AbbVie Inc. ABBV	$17.0B	10%	Jun 2026
Merck & Co., Inc. MRK	$16.6B	5.1%	Jun 2026
AstraZeneca PLC AZN	$15.4B	6.4%	Jun 2026
Pfizer Inc. PFE	$15.0B	2.6%	Jun 2026
Novartis AG NVS	$15.0B	0.8%	Jun 2026
Bristol-Myers Squibb Company BMY	$13.0B	5.7%	Jun 2026
Sanofi SNY	$12.3B	15%	Jun 2026
Amgen Inc. AMGN	$10.1B	9.5%	Jun 2026
GSK plc GSK	$8.4B	5.3%	Jun 2026
Gilead Sciences, Inc. GILD	$7.8B	10%	Jun 2026
Biogen Inc. BIIB	$2.7B	3.4%	Jun 2026
Grifols, S.A. GRFS	$1.7B	-4.8%	Jun 2026
Organon & Co. OGN	$1.5B	-3.5%	Mar 2026
Amarin Corporation plc AMRN	$45M	7.1%	Mar 2026

Full 20-quarter history · every available company

Revenue · reported quarter history

Showing the 12 largest of 16 companies with a series here. The remaining 4 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

AbbVie Inc. · ABBV

Sep 2021$14.3B

Dec 2021$14.9B

Mar 2022$13.5B

Jun 2022$14.6B

Sep 2022$14.8B

Dec 2022$15.1B

Mar 2023$12.2B

Jun 2023$13.9B

Sep 2023$13.9B

Dec 2023$14.3B

Mar 2024$12.3B

Jun 2024$14.5B

Sep 2024$14.5B

Dec 2024$15.1B

Mar 2025$13.3B

Jun 2025$15.4B

Sep 2025$15.8B

Dec 2025$16.6B

Mar 2026$15.0B

Jun 2026$17.0B

Amgen Inc. · AMGN

Sep 2021$6.7B

Dec 2021$6.8B

Mar 2022$6.2B

Jun 2022$6.6B

Sep 2022$6.7B

Dec 2022$6.8B

Mar 2023$6.1B

Jun 2023$7.0B

Sep 2023$6.9B

Dec 2023$8.2B

Mar 2024$7.4B

Jun 2024$8.4B

Sep 2024$8.5B

Dec 2024$9.1B

Mar 2025$8.1B

Jun 2025$9.2B

Sep 2025$9.6B

Dec 2025$9.9B

Mar 2026$8.6B

Jun 2026$10.1B

AstraZeneca PLC · AZN

Sep 2021$9.9B

Dec 2021$12.0B

Mar 2022$11.4B

Jun 2022$10.8B

Sep 2022$11.0B

Dec 2022$11.2B

Mar 2023$10.9B

Jun 2023$11.4B

Sep 2023$11.5B

Dec 2023$12.0B

Mar 2024$12.7B

Jun 2024$12.9B

Sep 2024$13.6B

Dec 2024$14.9B

Mar 2025$13.6B

Jun 2025$14.5B

Sep 2025$15.2B

Dec 2025$15.5B

Mar 2026$15.3B

Jun 2026$15.4B

Bristol-Myers Squibb Company · BMY

Sep 2021$11.6B

Dec 2021$12.0B

Mar 2022$11.6B

Jun 2022$11.9B

Sep 2022$11.2B

Dec 2022$11.4B

Mar 2023$11.3B

Jun 2023$11.2B

Sep 2023$11.0B

Dec 2023$11.5B

Mar 2024$11.9B

Jun 2024$12.2B

Sep 2024$11.9B

Dec 2024$12.3B

Mar 2025$11.2B

Jun 2025$12.3B

Sep 2025$12.2B

Dec 2025$12.5B

Mar 2026$11.5B

Jun 2026$13.0B

Eli Lilly and Company · LLY

Sep 2021$6.8B

Dec 2021$8.0B

Mar 2022$7.8B

Jun 2022$6.5B

Sep 2022$6.9B

Dec 2022$7.3B

Mar 2023$7.0B

Jun 2023$8.3B

Sep 2023$9.5B

Dec 2023$9.4B

Mar 2024$8.8B

Jun 2024$11.3B

Sep 2024$11.4B

Dec 2024$13.5B

Mar 2025$12.7B

Jun 2025$15.6B

Sep 2025$17.6B

Dec 2025$19.3B

Mar 2026$19.8B

Jun 2026$23.0B

Gilead Sciences, Inc. · GILD

Sep 2021$7.4B

Dec 2021$7.2B

Mar 2022$6.6B

Jun 2022$6.3B

Sep 2022$7.0B

Dec 2022$7.4B

Mar 2023$6.4B

Jun 2023$6.6B

Sep 2023$7.1B

Dec 2023$7.1B

Mar 2024$6.7B

Jun 2024$7.0B

Sep 2024$7.5B

Dec 2024$7.6B

Mar 2025$6.7B

Jun 2025$7.1B

Sep 2025$7.8B

Dec 2025$7.9B

Mar 2026$7.0B

Jun 2026$7.8B

GSK plc · GSK

Sep 2021$6.6B

Dec 2021$7.1B

Mar 2022$7.2B

Jun 2022$6.9B

Sep 2022$7.8B

Dec 2022$7.4B

Mar 2023$7.0B

Jun 2023$7.2B

Sep 2023$8.1B

Dec 2023$8.1B

Mar 2024$7.4B

Jun 2024$7.9B

Sep 2024$8.0B

Dec 2024$8.1B

Mar 2025$7.5B

Jun 2025$8.0B

Sep 2025$8.5B

Dec 2025$8.6B

Mar 2026$7.6B

Jun 2026$8.4B

Johnson & Johnson · JNJ

Sep 2021$23.3B

Dec 2021$23.3B

Mar 2022$24.8B

Jun 2022$23.4B

Sep 2022—

Dec 2022$20.0B

Mar 2023—

Jun 2023$20.9B

Sep 2023$21.5B

Dec 2023$21.4B

Mar 2024$21.4B

Jun 2024$22.4B

Sep 2024$22.5B

Dec 2024$22.5B

Mar 2025$21.9B

Jun 2025$23.7B

Sep 2025$24.0B

Dec 2025$24.6B

Mar 2026$24.1B

Jun 2026$25.3B

Merck & Co., Inc. · MRK

Sep 2021$13.2B

Dec 2021$13.5B

Mar 2022$15.9B

Jun 2022$14.6B

Sep 2022$15.0B

Dec 2022$13.8B

Mar 2023$14.5B

Jun 2023$15.0B

Sep 2023$16.0B

Dec 2023$14.6B

Mar 2024$15.8B

Jun 2024$16.1B

Sep 2024$16.7B

Dec 2024$15.6B

Mar 2025$15.5B

Jun 2025$15.8B

Sep 2025$17.3B

Dec 2025$16.4B

Mar 2026$16.3B

Jun 2026$16.6B

Novartis AG · NVS

Sep 2021$13.4B

Dec 2021$13.5B

Mar 2022$12.8B

Jun 2022—

Sep 2022$10.8B

Dec 2022$11.0B

Mar 2023$11.0B

Jun 2023$11.7B

Sep 2023$12.1B

Dec 2023$11.8B

Mar 2024$12.1B

Jun 2024$12.9B

Sep 2024$13.2B

Dec 2024$13.6B

Mar 2025$13.6B

Jun 2025$14.8B

Sep 2025$14.4B

Dec 2025$13.9B

Mar 2026$13.5B

Jun 2026$15.0B

Pfizer Inc. · PFE

Sep 2021$18.9B

Dec 2021$24.0B

Mar 2022—

Jun 2022$25.7B

Sep 2022$27.7B

Dec 2022$22.6B

Mar 2023—

Jun 2023$18.5B

Sep 2023$13.0B

Dec 2023$13.5B

Mar 2024$14.9B

Jun 2024$13.3B

Sep 2024$17.7B

Dec 2024$17.8B

Mar 2025$13.7B

Jun 2025$14.7B

Sep 2025$16.7B

Dec 2025$17.6B

Mar 2026$14.5B

Jun 2026$15.0B

Sanofi · SNY

Sep 2021$10.8B

Dec 2021$10.4B

Mar 2022$10.1B

Jun 2022$10.7B

Sep 2022$13.1B

Dec 2022$11.5B

Mar 2023$9.5B

Jun 2023$10.7B

Sep 2023$11.5B

Dec 2023$12.2B

Mar 2024$9.7B

Jun 2024$11.4B

Sep 2024$13.0B

Dec 2024$11.4B

Mar 2025$10.6B

Jun 2025$10.7B

Sep 2025$13.2B

Dec 2025$12.2B

Mar 2026$11.2B

Jun 2026$12.3B

Revenue growth · reported quarter history

Showing the 12 largest of 16 companies with a series here. The remaining 4 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

AbbVie Inc. · ABBV

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20224.5%

Sep 20223.3%

Dec 20221.6%

Mar 2023-9.7%

Jun 2023-4.9%

Sep 2023-6.0%

Dec 2023-5.4%

Mar 20240.7%

Jun 20244.3%

Sep 20243.8%

Dec 20245.6%

Mar 20258.4%

Jun 20256.7%

Sep 20259.1%

Dec 202510%

Mar 202612%

Jun 202610%

Amgen Inc. · AMGN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20221.0%

Sep 2022-0.8%

Dec 2022-0.1%

Mar 2023-2.1%

Jun 20235.9%

Sep 20233.8%

Dec 202320%

Mar 202422%

Jun 202420%

Sep 202423%

Dec 202411%

Mar 20259.4%

Jun 20259.4%

Sep 202512%

Dec 20258.6%

Mar 20265.8%

Jun 20269.5%

AstraZeneca PLC · AZN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202231%

Sep 202211%

Dec 2022-6.7%

Mar 2023-4.5%

Jun 20236.0%

Sep 20234.6%

Dec 20237.3%

Mar 202417%

Jun 202413%

Sep 202418%

Dec 202424%

Mar 20257.2%

Jun 202512%

Sep 202512%

Dec 20254.1%

Mar 202613%

Jun 20266.4%

Bristol-Myers Squibb Company · BMY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20221.6%

Sep 2022-3.5%

Dec 2022-4.8%

Mar 2023-2.7%

Jun 2023-5.6%

Sep 2023-2.3%

Dec 20230.6%

Mar 20244.7%

Jun 20248.7%

Sep 20248.4%

Dec 20247.5%

Mar 2025-5.6%

Jun 20250.6%

Sep 20252.8%

Dec 20251.3%

Mar 20262.6%

Jun 20265.7%

Eli Lilly and Company · LLY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-3.7%

Sep 20222.5%

Dec 2022-8.7%

Mar 2023-11%

Jun 202328%

Sep 202337%

Dec 202328%

Mar 202426%

Jun 202436%

Sep 202420%

Dec 202445%

Mar 202545%

Jun 202538%

Sep 202554%

Dec 202543%

Mar 202656%

Jun 202648%

Gilead Sciences, Inc. · GILD

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20220.7%

Sep 2022-5.1%

Dec 20222.0%

Mar 2023-3.6%

Jun 20235.4%

Sep 20230.1%

Dec 2023-3.7%

Mar 20245.3%

Jun 20245.4%

Sep 20247.0%

Dec 20246.4%

Mar 2025-0.3%

Jun 20251.8%

Sep 20253.0%

Dec 20254.7%

Mar 20264.4%

Jun 202610%

GSK plc · GSK

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202219%

Sep 202218%

Dec 20224.2%

Mar 2023-3.3%

Jun 20233.6%

Sep 20234.1%

Dec 20239.2%

Mar 20245.9%

Jun 20249.8%

Sep 2024-1.7%

Dec 20240.8%

Mar 20252.1%

Jun 20251.3%

Sep 20256.7%

Dec 20256.2%

Mar 20261.5%

Jun 20265.3%

Johnson & Johnson · JNJ

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022-14%

Mar 2023—

Jun 2023-11%

Sep 2023—

Dec 20236.8%

Mar 2024—

Jun 20247.4%

Sep 20244.4%

Dec 20245.5%

Mar 20252.4%

Jun 20255.8%

Sep 20256.8%

Dec 20259.1%

Mar 20269.9%

Jun 20266.6%

Merck & Co., Inc. · MRK

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202228%

Sep 202214%

Dec 20222.3%

Mar 2023-8.9%

Jun 20233.0%

Sep 20236.7%

Dec 20235.8%

Mar 20248.9%

Jun 20247.2%

Sep 20244.4%

Dec 20246.8%

Mar 2025-1.6%

Jun 2025-1.9%

Sep 20253.7%

Dec 20255.0%

Mar 20264.9%

Jun 20265.1%

Novartis AG · NVS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022-19%

Dec 2022-19%

Mar 2023-14%

Jun 2023—

Sep 202312%

Dec 20237.4%

Mar 20249.7%

Jun 20249.6%

Sep 20248.9%

Dec 202415%

Mar 202512%

Jun 202515%

Sep 20259.0%

Dec 20252.2%

Mar 2026-0.7%

Jun 20260.8%

Pfizer Inc. · PFE

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 202247%

Dec 2022-5.8%

Mar 2023—

Jun 2023-28%

Sep 2023-53%

Dec 2023-40%

Mar 2024—

Jun 2024-28%

Sep 202436%

Dec 202432%

Mar 2025-7.8%

Jun 202510%

Sep 2025-5.9%

Dec 2025-1.2%

Mar 20265.4%

Jun 20262.6%

Sanofi · SNY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202219%

Sep 202221%

Dec 202210%

Mar 2023-5.8%

Jun 2023-0.6%

Sep 2023-12%

Dec 20236.5%

Mar 20242.7%

Jun 20246.5%

Sep 202412%

Dec 2024-6.4%

Mar 20259.1%

Jun 2025-5.7%

Sep 20251.5%

Dec 20256.9%

Mar 20266.0%

Jun 202615%

06 · compare level, then change

Operating Economics & Margin Trend

Eli Lilly and Company has the highest OPM among the 16 Drug Manufacturers - General companies compared here, at 54.2%. AbbVie Inc. is next at 40%. Amarin Corporation plc has the highest Margin change at +14.8 percentage points, so level and change sit with different companies. 16 of 16 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Eli Lilly and Company leads opm at 54.2%; Amarin Corporation plc leads margin change at +14.8 percentage points.

LeaderEli Lilly and Company · 54.2%

Gap35.5% versus #2 · AbbVie Inc.

Persistence8/8 recent comparable periods

Coverage16/16 companies · 312 observations

Investor read: Eli Lilly and Company sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

OPMhighest

1Eli Lilly and Company LLY54%

2AbbVie Inc. ABBV40%

3Amgen Inc. AMGN36%

4Novartis AG NVS35%

5Gilead Sciences, Inc. GILD34%

Margin changefastest expanders

1Amarin Corporation plc AMRN+14.8 pp

2Bristol-Myers Squibb Company BMY+12.5 pp

3Eli Lilly and Company LLY+9.1 pp

4Amgen Inc. AMGN+2.9 pp

5AbbVie Inc. ABBV+2.5 pp

Operating margin · company comparison

16/16 level · 16/16 change

All-company data · latest reported quarter

Company	OPM	Margin change	Reported
Eli Lilly and Company LLY	54%	+9.1 pp	Jun 2026
AbbVie Inc. ABBV	40%	+2.5 pp	Jun 2026
Amgen Inc. AMGN	36%	+2.9 pp	Jun 2026
Novartis AG NVS	35%	+0.8 pp	Jun 2026
Gilead Sciences, Inc. GILD	34%	−5.5 pp	Jun 2026
Bristol-Myers Squibb Company BMY	31%	+12.5 pp	Jun 2026
Johnson & Johnson JNJ	29%	+0.9 pp	Jun 2026
AstraZeneca PLC AZN	24%	−0.8 pp	Jun 2026
Organon & Co. OGN	16%	+0.7 pp	Mar 2026
Grifols, S.A. GRFS	15%	−0.3 pp	Jun 2026
Sanofi SNY	8.5%	−5.2 pp	Jun 2026
GSK plc GSK	5.7%	−19.6 pp	Jun 2026
Biogen Inc. BIIB	5.6%	−24.9 pp	Jun 2026
Merck & Co., Inc. MRK	-0.2%	−37.7 pp	Jun 2026
Pfizer Inc. PFE	-4.3%	−25.1 pp	Jun 2026
Amarin Corporation plc AMRN	-25%	+14.8 pp	Mar 2026

Full 20-quarter history · every available company

OPM · reported quarter history

Showing the 12 largest of 16 companies with a series here. The remaining 4 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

AbbVie Inc. · ABBV

Sep 202134%

Dec 202146%

Mar 202239%

Jun 202239%

Sep 202234%

Dec 202240%

Mar 202330%

Jun 202336%

Sep 202333%

Dec 202331%

Mar 202427%

Jun 202435%

Sep 202429%

Dec 202433%

Mar 202530%

Jun 202538%

Sep 202536%

Dec 202534%

Mar 202632%

Jun 202640%

Amgen Inc. · AMGN

Sep 202135%

Dec 202134%

Mar 202240%

Jun 202233%

Sep 202240%

Dec 202231%

Mar 202334%

Jun 202338%

Sep 202327%

Dec 202339%

Mar 202424%

Jun 202431%

Sep 202432%

Dec 202429%

Mar 202529%

Jun 202533%

Sep 202534%

Dec 202531%

Mar 202634%

Jun 202636%

AstraZeneca PLC · AZN

Sep 2021-5.1%

Dec 202131%

Mar 202213%

Jun 20225.0%

Sep 202211%

Dec 202251%

Mar 202323%

Jun 202322%

Sep 202317%

Dec 202328%

Mar 202425%

Jun 202421%

Sep 202416%

Dec 202433%

Mar 202527%

Jun 202524%

Sep 202524%

Dec 202522%

Mar 202628%

Jun 202624%

Bristol-Myers Squibb Company · BMY

Sep 202115%

Dec 202119%

Mar 202220%

Jun 202219%

Sep 202218%

Dec 202214%

Mar 202321%

Jun 202316%

Sep 202317%

Dec 202311%

Mar 2024-96%

Jun 202413%

Sep 202416%

Dec 20243.9%

Mar 202530%

Jun 202519%

Sep 202525%

Dec 202511%

Mar 202629%

Jun 202631%

Eli Lilly and Company · LLY

Sep 202132%

Dec 202131%

Mar 202234%

Jun 202227%

Sep 202229%

Dec 202230%

Mar 202325%

Jun 202328%

Sep 202337%

Dec 202334%

Mar 202431%

Jun 202439%

Sep 202440%

Dec 202439%

Mar 202542%

Jun 202545%

Sep 202548%

Dec 202545%

Mar 202649%

Jun 202654%

Gilead Sciences, Inc. · GILD

Sep 202150%

Dec 202140%

Mar 202244%

Jun 202238%

Sep 202247%

Dec 202232%

Mar 202334%

Jun 202329%

Sep 202339%

Dec 202336%

Mar 202434%

Jun 202439%

Sep 202442%

Dec 202433%

Mar 202539%

Jun 202539%

Sep 202545%

Dec 202537%

Mar 202639%

Jun 202634%

GSK plc · GSK

Sep 202121%

Dec 20217.0%

Mar 202232%

Jun 202216%

Sep 202215%

Dec 202225%

Mar 202330%

Jun 202330%

Sep 202324%

Dec 20237.1%

Mar 202420%

Jun 202421%

Sep 20242.4%

Dec 20248.6%

Mar 202530%

Jun 202525%

Sep 202530%

Dec 202513%

Mar 202630%

Jun 20265.7%

Johnson & Johnson · JNJ

Sep 202127%

Dec 202129%

Mar 202220%

Jun 202229%

Sep 2022—

Dec 202228%

Mar 2023—

Jun 202331%

Sep 202329%

Dec 202330%

Mar 202430%

Jun 202429%

Sep 202425%

Dec 202418%

Mar 202529%

Jun 202528%

Sep 202530%

Dec 202524%

Mar 202627%

Jun 202629%

Merck & Co., Inc. · MRK

Sep 202138%

Dec 202127%

Mar 202237%

Jun 202236%

Sep 202234%

Dec 202231%

Mar 202336%

Jun 202339%

Sep 202338%

Dec 2023-4.5%

Mar 202443%

Jun 202440%

Sep 202426%

Dec 202452%

Mar 202540%

Jun 202538%

Sep 202541%

Dec 202533%

Mar 202639%

Jun 2026-0.2%

Novartis AG · NVS

Sep 202124%

Dec 202133%

Mar 202223%

Jun 2022—

Sep 202218%

Dec 202244%

Mar 202319%

Jun 202325%

Sep 202314%

Dec 202352%

Mar 202428%

Jun 202431%

Sep 202428%

Dec 202439%

Mar 202535%

Jun 202534%

Sep 202532%

Dec 202528%

Mar 202631%

Jun 202635%

Pfizer Inc. · PFE

Sep 202137%

Dec 202133%

Mar 2022—

Jun 202235%

Sep 202241%

Dec 202240%

Mar 2023—

Jun 202334%

Sep 202317%

Dec 2023-25%

Mar 202423%

Jun 2024-0.8%

Sep 202427%

Dec 2024-0.1%

Mar 202520%

Jun 202521%

Sep 202520%

Dec 2025-9.4%

Mar 202622%

Jun 2026-4.3%

Sanofi · SNY

Sep 202128%

Dec 202114%

Mar 202224%

Jun 202213%

Sep 202221%

Dec 202236%

Mar 202322%

Jun 202317%

Sep 202326%

Dec 20232.8%

Mar 202413%

Jun 202414%

Sep 202427%

Dec 20248.3%

Mar 202522%

Jun 202514%

Sep 202528%

Dec 2025-8.5%

Mar 202619%

Jun 20268.5%

Margin change · reported quarter history

Showing the 12 largest of 16 companies with a series here. The remaining 4 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

AbbVie Inc. · ABBV

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+7.5 pp

Sep 2022−0.2 pp

Dec 2022−5.2 pp

Mar 2023−8.5 pp

Jun 2023−3.7 pp

Sep 2023−1.2 pp

Dec 2023−9.1 pp

Mar 2024−2.6 pp

Jun 2024−1.0 pp

Sep 2024−4.2 pp

Dec 2024+1.2 pp

Mar 2025+3.0 pp

Jun 2025+2.9 pp

Sep 2025+6.9 pp

Dec 2025+1.6 pp

Mar 2026+1.8 pp

Jun 2026+2.5 pp

Amgen Inc. · AMGN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+20.3 pp

Sep 2022+4.6 pp

Dec 2022−3.1 pp

Mar 2023−6.0 pp

Jun 2023+5.1 pp

Sep 2023−12.8 pp

Dec 2023+7.7 pp

Mar 2024−10.4 pp

Jun 2024−7.5 pp

Sep 2024+4.7 pp

Dec 2024−10.4 pp

Mar 2025+5.2 pp

Jun 2025+2.0 pp

Sep 2025+2.4 pp

Dec 2025+1.9 pp

Mar 2026+5.1 pp

Jun 2026+2.9 pp

AstraZeneca PLC · AZN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022−8.7 pp

Sep 2022+16.4 pp

Dec 2022+20.2 pp

Mar 2023+10.0 pp

Jun 2023+16.5 pp

Sep 2023+5.7 pp

Dec 2023−23.0 pp

Mar 2024+1.2 pp

Jun 2024−0.3 pp

Sep 2024−1.5 pp

Dec 2024+5.5 pp

Mar 2025+2.0 pp

Jun 2025+3.1 pp

Sep 2025+8.6 pp

Dec 2025−11.7 pp

Mar 2026+1.3 pp

Jun 2026−0.8 pp

Bristol-Myers Squibb Company · BMY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+5.6 pp

Sep 2022+3.4 pp

Dec 2022−4.4 pp

Mar 2023+0.7 pp

Jun 2023−3.4 pp

Sep 2023−1.3 pp

Dec 2023−3.0 pp

Mar 2024−117.2 pp

Jun 2024−2.7 pp

Sep 2024−1.0 pp

Dec 2024−7.5 pp

Mar 2025+125.9 pp

Jun 2025+5.7 pp

Sep 2025+8.5 pp

Dec 2025+7.5 pp

Mar 2026−1.0 pp

Jun 2026+12.5 pp

Eli Lilly and Company · LLY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+6.1 pp

Sep 2022−2.1 pp

Dec 2022−0.3 pp

Mar 2023−9.5 pp

Jun 2023+1.2 pp

Sep 2023+7.9 pp

Dec 2023+3.9 pp

Mar 2024+6.6 pp

Jun 2024+11.0 pp

Sep 2024+2.5 pp

Dec 2024+5.3 pp

Mar 2025+10.5 pp

Jun 2025+6.0 pp

Sep 2025+8.5 pp

Dec 2025+5.5 pp

Mar 2026+7.7 pp

Jun 2026+9.1 pp

Gilead Sciences, Inc. · GILD

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+1.6 pp

Sep 2022−3.2 pp

Dec 2022−7.2 pp

Mar 2023−9.8 pp

Jun 2023−8.8 pp

Sep 2023−8.6 pp

Dec 2023+3.2 pp

Mar 20240.0 pp

Jun 2024+9.8 pp

Sep 2024+3.6 pp

Dec 2024−2.3 pp

Mar 2025+4.1 pp

Jun 2025+0.5 pp

Sep 2025+3.1 pp

Dec 2025+4.2 pp

Mar 2026+0.8 pp

Jun 2026−5.5 pp

GSK plc · GSK

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022−6.2 pp

Sep 2022−5.6 pp

Dec 2022+18.3 pp

Mar 2023−1.9 pp

Jun 2023+14.2 pp

Sep 2023+8.7 pp

Dec 2023−18.2 pp

Mar 2024−9.8 pp

Jun 2024−8.9 pp

Sep 2024−21.5 pp

Dec 2024+1.5 pp

Mar 2025+9.3 pp

Jun 2025+4.4 pp

Sep 2025+27.9 pp

Dec 2025+4.2 pp

Mar 2026+0.6 pp

Jun 2026−19.6 pp

Johnson & Johnson · JNJ

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022−1.0 pp

Mar 2023—

Jun 2023+1.9 pp

Sep 2023—

Dec 2023+1.6 pp

Mar 2024—

Jun 2024−1.6 pp

Sep 2024−4.9 pp

Dec 2024−11.7 pp

Mar 2025−0.6 pp

Jun 2025−0.7 pp

Sep 2025+5.7 pp

Dec 2025+5.8 pp

Mar 2026−1.5 pp

Jun 2026+0.9 pp

Merck & Co., Inc. · MRK

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+21.5 pp

Sep 2022−4.0 pp

Dec 2022+4.7 pp

Mar 2023−1.1 pp

Jun 2023+3.4 pp

Sep 2023+3.8 pp

Dec 2023−35.8 pp

Mar 2024+7.0 pp

Jun 2024+0.5 pp

Sep 2024−11.9 pp

Dec 2024+56.3 pp

Mar 2025−2.4 pp

Jun 2025−2.1 pp

Sep 2025+14.6 pp

Dec 2025−19.0 pp

Mar 2026−1.5 pp

Jun 2026−37.7 pp

Novartis AG · NVS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−5.9 pp

Dec 2022+11.8 pp

Mar 2023−3.7 pp

Jun 2023—

Sep 2023−4.1 pp

Dec 2023+7.1 pp

Mar 2024+9.1 pp

Jun 2024+6.2 pp

Sep 2024+13.8 pp

Dec 2024−12.4 pp

Mar 2025+6.5 pp

Jun 2025+2.8 pp

Sep 2025+4.3 pp

Dec 2025−11.3 pp

Mar 2026−4.0 pp

Jun 2026+0.8 pp

Pfizer Inc. · PFE

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+4.5 pp

Dec 2022+7.2 pp

Mar 2023—

Jun 2023−1.4 pp

Sep 2023−23.9 pp

Dec 2023−64.6 pp

Mar 2024—

Jun 2024−34.7 pp

Sep 2024+9.2 pp

Dec 2024+24.7 pp

Mar 2025−2.7 pp

Jun 2025+21.6 pp

Sep 2025−6.6 pp

Dec 2025−9.3 pp

Mar 2026+1.6 pp

Jun 2026−25.1 pp

Sanofi · SNY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022−3.9 pp

Sep 2022−7.4 pp

Dec 2022+21.6 pp

Mar 2023−1.9 pp

Jun 2023+4.1 pp

Sep 2023+5.6 pp

Dec 2023−33.0 pp

Mar 2024−9.2 pp

Jun 2024−3.4 pp

Sep 2024+1.0 pp

Dec 2024+5.5 pp

Mar 2025+8.8 pp

Jun 2025−0.3 pp

Sep 2025+0.2 pp

Dec 2025−16.8 pp

Mar 2026−2.6 pp

Jun 2026−5.2 pp

07 · compare level, then change

Profit Scale & Acceleration

Eli Lilly and Company has the highest Net profit among the 16 Drug Manufacturers - General companies compared here, at $26,712 million. Johnson & Johnson is next at $21,037 million. The same company also holds the highest Profit growth, at 93.6%. 15 of 16 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Eli Lilly and Company leads with $26,712 million of TTM profit, 27% above Johnson & Johnson. Eli Lilly and Company shows 93.6% growth from a $26,712 million profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderEli Lilly and Company · $26,712 million

Gap27% versus #2 · Johnson & Johnson

Persistence8/8 recent comparable periods

Coverage15/16 companies · 312 observations

Investor read: Eli Lilly and Company sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profitlargest

1Eli Lilly and Company LLY$26.7B

2Johnson & Johnson JNJ$21.0B

3Novartis AG NVS$12.7B

4AstraZeneca PLC AZN$10.4B

5Bristol-Myers Squibb Company BMY$9.3B

Profit growthfastest growers

1Eli Lilly and Company LLY94%

2Bristol-Myers Squibb Company BMY83%

3AbbVie Inc. ABBV68%

4Amgen Inc. AMGN32%

5GSK plc GSK32%

Net profit · company comparison

15/16 level · 14/16 change

All-company data · latest reported quarter

Company	Net profit	Profit growth	Reported
Eli Lilly and Company LLY	$7.1B	25%	Jun 2026
Johnson & Johnson JNJ	$5.5B	-0.1%	Jun 2026
AbbVie Inc. ABBV	$3.6B	288%	Jun 2026
Bristol-Myers Squibb Company BMY	$3.3B	153%	Jun 2026
Novartis AG NVS	$3.3B	-19%	Jun 2026
AstraZeneca PLC AZN	$2.5B	2.3%	Jun 2026
Amgen Inc. AMGN	$2.4B	66%	Jun 2026
GSK plc GSK	$553M	-66%	Jun 2026
Sanofi SNY	$386M	-68%	Jun 2026
Organon & Co. OGN	$146M	68%	Mar 2026
Biogen Inc. BIIB	$98M	-85%	Jun 2026
Grifols, S.A. GRFS	$88M	-4.4%	Jun 2026
Amarin Corporation plc AMRN	$-11M	-800%	Mar 2026
Pfizer Inc. PFE	$-246M	-108%	Jun 2026
Merck & Co., Inc. MRK	$-1.3B	-130%	Jun 2026
Gilead Sciences, Inc. GILD	$-10.5B	-636%	Jun 2026

Full 20-quarter history · every available company

Net profit · reported quarter history

Showing the 12 largest of 16 companies with a series here. The remaining 4 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

AbbVie Inc. · ABBV

Sep 2021$3.2B

Dec 2021$4.0B

Mar 2022$4.5B

Jun 2022$913M

Sep 2022$3.9B

Dec 2022$2.5B

Mar 2023$228M

Jun 2023$2.0B

Sep 2023$1.8B

Dec 2023$811M

Mar 2024$1.4B

Jun 2024$1.4B

Sep 2024$1.6B

Dec 2024$-32M

Mar 2025$1.3B

Jun 2025$928M

Sep 2025$176M

Dec 2025$1.8B

Mar 2026$687M

Jun 2026$3.6B

Amgen Inc. · AMGN

Sep 2021$1.9B

Dec 2021$1.9B

Mar 2022$1.5B

Jun 2022$1.3B

Sep 2022$2.1B

Dec 2022$1.6B

Mar 2023$2.8B

Jun 2023$1.4B

Sep 2023$1.7B

Dec 2023$767M

Mar 2024$-113M

Jun 2024$746M

Sep 2024$2.8B

Dec 2024$627M

Mar 2025$1.7B

Jun 2025$1.4B

Sep 2025$3.2B

Dec 2025$1.3B

Mar 2026$1.8B

Jun 2026$2.4B

AstraZeneca PLC · AZN

Sep 2021$-1.7B

Dec 2021$-347M

Mar 2022$386M

Jun 2022$360M

Sep 2022$1.6B

Dec 2022$901M

Mar 2023$1.8B

Jun 2023$1.8B

Sep 2023$1.4B

Dec 2023$960M

Mar 2024$2.2B

Jun 2024$1.9B

Sep 2024$1.4B

Dec 2024$1.5B

Mar 2025$2.9B

Jun 2025$2.5B

Sep 2025$2.5B

Dec 2025$2.3B

Mar 2026$3.1B

Jun 2026$2.5B

Bristol-Myers Squibb Company · BMY

Sep 2021$1.6B

Dec 2021$2.4B

Mar 2022$1.3B

Jun 2022$1.4B

Sep 2022$1.6B

Dec 2022$2.0B

Mar 2023$2.3B

Jun 2023$2.1B

Sep 2023$1.9B

Dec 2023$1.8B

Mar 2024$-11.9B

Jun 2024$1.7B

Sep 2024$1.2B

Dec 2024$76M

Mar 2025$2.5B

Jun 2025$1.3B

Sep 2025$2.2B

Dec 2025$1.1B

Mar 2026$2.7B

Jun 2026$3.3B

Eli Lilly and Company · LLY

Sep 2021$1.1B

Dec 2021$1.7B

Mar 2022$1.9B

Jun 2022$953M

Sep 2022$1.5B

Dec 2022$1.9B

Mar 2023$1.3B

Jun 2023$1.8B

Sep 2023$-57M

Dec 2023$2.2B

Mar 2024$2.2B

Jun 2024$3.0B

Sep 2024$970M

Dec 2024$4.4B

Mar 2025$2.8B

Jun 2025$5.7B

Sep 2025$5.6B

Dec 2025$6.6B

Mar 2026$7.4B

Jun 2026$7.1B

Gilead Sciences, Inc. · GILD

Sep 2021$2.6B

Dec 2021$382M

Mar 2022$19M

Jun 2022$1.1B

Sep 2022$1.8B

Dec 2022$1.6B

Mar 2023$1.0B

Jun 2023$1.0B

Sep 2023$2.2B

Dec 2023$1.4B

Mar 2024$-4.2B

Jun 2024$1.6B

Sep 2024$1.3B

Dec 2024$1.8B

Mar 2025$1.3B

Jun 2025$2.0B

Sep 2025$3.1B

Dec 2025$2.2B

Mar 2026$2.0B

Jun 2026$-10.5B

GSK plc · GSK

Sep 2021$946M

Dec 2021$420M

Mar 2022$1.8B

Jun 2022$746M

Sep 2022$779M

Dec 2022$1.6B

Mar 2023$1.6B

Jun 2023$1.7B

Sep 2023$1.5B

Dec 2023$398M

Mar 2024$1.1B

Jun 2024$1.3B

Sep 2024$65M

Dec 2024$501M

Mar 2025$1.8B

Jun 2025$1.6B

Sep 2025$2.1B

Dec 2025$727M

Mar 2026$1.8B

Jun 2026$553M

Johnson & Johnson · JNJ

Sep 2021$6.3B

Dec 2021$3.7B

Mar 2022$4.7B

Jun 2022$5.1B

Sep 2022—

Dec 2022$4.5B

Mar 2023—

Jun 2023$-68M

Sep 2023$5.1B

Dec 2023$26.0B

Mar 2024$3.3B

Jun 2024$4.7B

Sep 2024$2.7B

Dec 2024$3.4B

Mar 2025$11.0B

Jun 2025$5.5B

Sep 2025$5.2B

Dec 2025$5.1B

Mar 2026$5.2B

Jun 2026$5.5B

Merck & Co., Inc. · MRK

Sep 2021$4.6B

Dec 2021$3.8B

Mar 2022$4.3B

Jun 2022$3.9B

Sep 2022$3.3B

Dec 2022$3.0B

Mar 2023$2.8B

Jun 2023$-6.0B

Sep 2023$4.8B

Dec 2023$-1.2B

Mar 2024$4.8B

Jun 2024$5.5B

Sep 2024$3.2B

Dec 2024$3.7B

Mar 2025$5.1B

Jun 2025$4.4B

Sep 2025$5.8B

Dec 2025$3.0B

Mar 2026$-4.2B

Jun 2026$-1.3B

Novartis AG · NVS

Sep 2021$2.8B

Dec 2021$16.3B

Mar 2022$2.2B

Jun 2022—

Sep 2022$1.6B

Dec 2022$1.5B

Mar 2023$2.3B

Jun 2023$2.3B

Sep 2023$1.8B

Dec 2023$8.5B

Mar 2024$2.7B

Jun 2024$3.2B

Sep 2024$3.2B

Dec 2024$2.8B

Mar 2025$3.6B

Jun 2025$4.0B

Sep 2025$3.9B

Dec 2025$2.4B

Mar 2026$3.2B

Jun 2026$3.3B

Pfizer Inc. · PFE

Sep 2021$5.8B

Dec 2021$8.2B

Mar 2022—

Jun 2022$7.9B

Sep 2022$9.9B

Dec 2022$8.6B

Mar 2023—

Jun 2023$5.6B

Sep 2023$2.3B

Dec 2023$-2.4B

Mar 2024$3.1B

Jun 2024$31M

Sep 2024$4.5B

Dec 2024$411M

Mar 2025$3.0B

Jun 2025$2.9B

Sep 2025$3.6B

Dec 2025$-1.6B

Mar 2026$2.7B

Jun 2026$-246M

Sanofi · SNY

Sep 2021$2.3B

Dec 2021$1.1B

Mar 2022$2.0B

Jun 2022$1.2B

Sep 2022$2.1B

Dec 2022$3.2B

Mar 2023$1.8B

Jun 2023$1.5B

Sep 2023$2.3B

Dec 2023$-430M

Mar 2024$1.0B

Jun 2024$1.1B

Sep 2024$2.7B

Dec 2024$680M

Mar 2025$1.7B

Jun 2025$1.2B

Sep 2025$2.8B

Dec 2025$-569M

Mar 2026$1.6B

Jun 2026$386M

Profit growth · reported quarter history

Showing the 12 largest of 16 companies with a series here. The remaining 4 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

AbbVie Inc. · ABBV

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202219%

Sep 202224%

Dec 2022-39%

Mar 2023-95%

Jun 2023120%

Sep 2023-55%

Dec 2023-67%

Mar 2024496%

Jun 2024-32%

Sep 2024-12%

Dec 2024-104%

Mar 2025-6.1%

Jun 2025-32%

Sep 2025-89%

Dec 2025—

Mar 2026-46%

Jun 2026288%

Amgen Inc. · AMGN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022184%

Sep 202214%

Dec 2022-15%

Mar 202392%

Jun 20234.7%

Sep 2023-19%

Dec 2023-53%

Mar 2024-104%

Jun 2024-46%

Sep 202464%

Dec 2024-18%

Mar 2025—

Jun 202592%

Sep 202514%

Dec 2025113%

Mar 20265.1%

Jun 202666%

AstraZeneca PLC · AZN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-35%

Sep 2022—

Dec 2022—

Mar 2023367%

Jun 2023405%

Sep 2023-16%

Dec 20236.6%

Mar 202421%

Jun 20246.0%

Sep 20244.0%

Dec 202456%

Mar 202534%

Jun 202527%

Sep 202577%

Dec 202555%

Mar 20265.6%

Jun 20262.3%

Bristol-Myers Squibb Company · BMY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202235%

Sep 20223.6%

Dec 2022-15%

Mar 202377%

Jun 202345%

Sep 202320%

Dec 2023-13%

Mar 2024-625%

Jun 2024-19%

Sep 2024-37%

Dec 2024-96%

Mar 2025—

Jun 2025-22%

Sep 202581%

Dec 20251,328%

Mar 20268.8%

Jun 2026153%

Eli Lilly and Company · LLY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-31%

Sep 202231%

Dec 202212%

Mar 2023-29%

Jun 202385%

Sep 2023-104%

Dec 202313%

Mar 202467%

Jun 202468%

Sep 2024—

Dec 2024101%

Mar 202523%

Jun 202591%

Sep 2025476%

Dec 202551%

Mar 2026168%

Jun 202625%

Gilead Sciences, Inc. · GILD

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-25%

Sep 2022-31%

Dec 2022329%

Mar 20235,216%

Jun 2023-8.7%

Sep 202322%

Dec 2023-13%

Mar 2024-513%

Jun 202454%

Sep 2024-43%

Dec 202425%

Mar 2025—

Jun 202521%

Sep 2025144%

Dec 202522%

Mar 202654%

Jun 2026-636%

GSK plc · GSK

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-41%

Sep 2022-18%

Dec 2022287%

Mar 2023-7.9%

Jun 2023134%

Sep 202397%

Dec 2023-76%

Mar 2024-34%

Jun 2024-25%

Sep 2024-96%

Dec 202426%

Mar 202564%

Jun 202526%

Sep 20253,198%

Dec 202545%

Mar 20263.8%

Jun 2026-66%

Johnson & Johnson · JNJ

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 202222%

Mar 2023—

Jun 2023-101%

Sep 2023—

Dec 2023484%

Mar 2024—

Jun 2024—

Sep 2024-48%

Dec 2024-87%

Mar 2025238%

Jun 202518%

Sep 202591%

Dec 202549%

Mar 2026-52%

Jun 2026-0.1%

Merck & Co., Inc. · MRK

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022225%

Sep 2022-29%

Dec 2022-20%

Mar 2023-34%

Jun 2023-251%

Sep 202346%

Dec 2023-141%

Mar 202469%

Jun 2024—

Sep 2024-33%

Dec 2024—

Mar 20256.7%

Jun 2025-19%

Sep 202583%

Dec 2025-21%

Mar 2026-183%

Jun 2026-130%

Novartis AG · NVS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022-43%

Dec 2022-91%

Mar 20233.4%

Jun 2023—

Sep 202312%

Dec 2023478%

Mar 202417%

Jun 202440%

Sep 202481%

Dec 2024-67%

Mar 202534%

Jun 202524%

Sep 202523%

Dec 2025-15%

Mar 2026-13%

Jun 2026-19%

Pfizer Inc. · PFE

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 202270%

Dec 20225.8%

Mar 2023—

Jun 2023-29%

Sep 2023-76%

Dec 2023-128%

Mar 2024—

Jun 2024-99%

Sep 202492%

Dec 2024—

Mar 2025-5.0%

Jun 20259,265%

Sep 2025-21%

Dec 2025-499%

Mar 2026-8.9%

Jun 2026-108%

Sanofi · SNY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-0.8%

Sep 2022-12%

Dec 2022182%

Mar 2023-11%

Jun 202327%

Sep 202310%

Dec 2023-114%

Mar 2024-41%

Jun 2024-28%

Sep 202420%

Dec 2024—

Mar 202563%

Jun 20259.2%

Sep 20253.6%

Dec 2025-184%

Mar 2026-5.6%

Jun 2026-68%

08 · compare level, then change

Return On Capital Employed

Eli Lilly and Company has the highest ROCE among the 16 Drug Manufacturers - General companies compared here, at 41.7%. Gilead Sciences, Inc. is next at 30.9%. Johnson & Johnson has the highest ROCE change at +13.6 percentage points, so level and change sit with different companies. 16 of 16 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Eli Lilly and Company leads ROCE at 41.7%, 10.8 percentage points above Gilead Sciences, Inc.. Johnson & Johnson has the strongest latest improvement at +13.6 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderEli Lilly and Company · 41.7%

Gap35% versus #2 · Gilead Sciences, Inc.

Persistence8/8 recent comparable periods

Coverage16/16 companies · 311 observations

Investor read: Eli Lilly and Company sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

ROCEhighest

1Eli Lilly and Company LLY42%

2Gilead Sciences, Inc. GILD31%

3AbbVie Inc. ABBV25%

4Novartis AG NVS20%

5Johnson & Johnson JNJ19%

ROCE changefastest improvers

1Johnson & Johnson JNJ+13.6 pp

2Gilead Sciences, Inc. GILD+6.1 pp

3Eli Lilly and Company LLY+5.8 pp

4AbbVie Inc. ABBV+5.1 pp

5Bristol-Myers Squibb Company BMY+2.6 pp

Return on capital · company comparison

16/16 level · 16/16 change

All-company data · latest reported quarter

Company	ROCE	ROCE change	Reported
Eli Lilly and Company LLY	42%	+5.8 pp	Jun 2026
Gilead Sciences, Inc. GILD	31%	+6.1 pp	Jun 2026
AbbVie Inc. ABBV	25%	+5.1 pp	Jun 2026
Novartis AG NVS	20%	−6.1 pp	Jun 2026
Johnson & Johnson JNJ	19%	+13.6 pp	Jun 2026
Merck & Co., Inc. MRK	18%	−8.6 pp	Jun 2026
Amgen Inc. AMGN	18%	+2.4 pp	Jun 2026
AstraZeneca PLC AZN	18%	−0.3 pp	Jun 2026
Bristol-Myers Squibb Company BMY	5.9%	+2.6 pp	Jun 2026
Organon & Co. OGN	2.2%	−0.1 pp	Mar 2026
Grifols, S.A. GRFS	1.8%	−0.1 pp	Jun 2026
GSK plc GSK	1.2%	−4.1 pp	Jun 2026
Sanofi SNY	1.1%	−0.4 pp	Jun 2026
Biogen Inc. BIIB	0.6%	−2.7 pp	Jun 2026
Pfizer Inc. PFE	-0.4%	−2.2 pp	Jun 2026
Amarin Corporation plc AMRN	-2.4%	+0.8 pp	Mar 2026

Full 20-quarter history · every available company

ROCE · reported quarter history

Showing the 12 largest of 16 companies with a series here. The remaining 4 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

AbbVie Inc. · ABBV

Sep 202117%

Dec 202119%

Mar 202220%

Jun 202221%

Sep 202221%

Dec 202220%

Mar 202319%

Jun 202319%

Sep 202319%

Dec 202318%

Mar 202416%

Jun 202417%

Sep 202417%

Dec 202418%

Mar 202518%

Jun 202519%

Sep 202522%

Dec 202523%

Mar 202623%

Jun 202625%

Amgen Inc. · AMGN

Sep 202118%

Dec 202119%

Mar 202221%

Jun 202220%

Sep 202220%

Dec 202219%

Mar 202312%

Jun 202313%

Sep 202312%

Dec 202312%

Mar 202413%

Jun 202414%

Sep 202415%

Dec 202414%

Mar 202515%

Jun 202516%

Sep 202516%

Dec 202518%

Mar 202618%

Jun 202618%

AstraZeneca PLC · AZN

Sep 20212.7%

Dec 20216.5%

Mar 20227.5%

Jun 20227.0%

Sep 202210%

Dec 202213%

Mar 202314%

Jun 202317%

Sep 202319%

Dec 202315%

Mar 202415%

Jun 202415%

Sep 202414%

Dec 202417%

Mar 202517%

Jun 202518%

Sep 202520%

Dec 202517%

Mar 202618%

Jun 202618%

Bristol-Myers Squibb Company · BMY

Sep 20211.8%

Dec 20212.4%

Mar 20222.7%

Jun 20222.6%

Sep 20222.5%

Dec 20222.0%

Mar 20233.0%

Jun 20232.3%

Sep 20232.6%

Dec 20231.8%

Mar 2024-15%

Jun 20242.2%

Sep 20242.8%

Dec 20240.7%

Mar 20254.7%

Jun 20253.3%

Sep 20254.3%

Dec 20252.1%

Mar 20264.8%

Jun 20265.9%

Eli Lilly and Company · LLY

Sep 202124%

Dec 202125%

Mar 202227%

Jun 202229%

Sep 202228%

Dec 202227%

Mar 202321%

Jun 202323%

Sep 202327%

Dec 202329%

Mar 202426%

Jun 202431%

Sep 202429%

Dec 202434%

Mar 202533%

Jun 202536%

Sep 202535%

Dec 202538%

Mar 202643%

Jun 202642%

Gilead Sciences, Inc. · GILD

Sep 202123%

Dec 202121%

Mar 202222%

Jun 202222%

Sep 202222%

Dec 202221%

Mar 202320%

Jun 202320%

Sep 202318%

Dec 202318%

Mar 202422%

Jun 202424%

Sep 202425%

Dec 202423%

Mar 202525%

Jun 202525%

Sep 202525%

Dec 202525%

Mar 202626%

Jun 202631%

GSK plc · GSK

Sep 20212.4%

Dec 20210.9%

Mar 20223.7%

Jun 20222.0%

Sep 20222.5%

Dec 20224.0%

Mar 20234.0%

Jun 20234.8%

Sep 20235.0%

Dec 20231.5%

Mar 20243.9%

Jun 20244.4%

Sep 20240.5%

Dec 20241.8%

Mar 20255.6%

Jun 20255.3%

Sep 20256.8%

Dec 20252.8%

Mar 20265.7%

Jun 20261.2%

Johnson & Johnson · JNJ

Sep 2021—

Dec 202118%

Mar 202218%

Jun 202219%

Sep 2022—

Dec 202214%

Mar 2023—

Jun 20238.9%

Sep 202313%

Dec 202316%

Mar 202419%

Jun 202419%

Sep 202418%

Dec 202417%

Mar 202516%

Jun 20255.0%

Sep 202517%

Dec 202518%

Mar 202619%

Jun 202619%

Merck & Co., Inc. · MRK

Sep 202120%

Dec 202119%

Mar 202222%

Jun 202223%

Sep 202224%

Dec 202224%

Mar 202323%

Jun 202325%

Sep 202326%

Dec 202320%

Mar 202422%

Jun 202421%

Sep 202419%

Dec 202429%

Mar 202528%

Jun 202527%

Sep 202527%

Dec 202523%

Mar 202624%

Jun 202618%

Novartis AG · NVS

Sep 202115%

Dec 202113%

Mar 202214%

Jun 2022—

Sep 202210%

Dec 202211%

Mar 202311%

Jun 202315%

Sep 202318%

Dec 202317%

Mar 202422%

Jun 202422%

Sep 202423%

Dec 202422%

Mar 202526%

Jun 202526%

Sep 202526%

Dec 202522%

Mar 202620%

Jun 202620%

Pfizer Inc. · PFE

Sep 2021—

Dec 20215.6%

Mar 2022—

Jun 20226.5%

Sep 20228.1%

Dec 20226.2%

Mar 2023—

Jun 20234.1%

Sep 20231.4%

Dec 2023-2.0%

Mar 20242.0%

Jun 2024-0.1%

Sep 20242.6%

Dec 20240.0%

Mar 20251.6%

Jun 20251.8%

Sep 20251.9%

Dec 2025-1.0%

Mar 20261.8%

Jun 2026-0.4%

Sanofi · SNY

Sep 20213.1%

Dec 20211.5%

Mar 20222.5%

Jun 20221.5%

Sep 20222.7%

Dec 20224.1%

Mar 20232.1%

Jun 20231.9%

Sep 20233.0%

Dec 20230.3%

Mar 20241.2%

Jun 20241.6%

Sep 20243.4%

Dec 20240.9%

Mar 20252.3%

Jun 20251.5%

Sep 20253.6%

Dec 2025-1.0%

Mar 20262.1%

Jun 20261.1%

ROCE change · reported quarter history

Showing the 12 largest of 16 companies with a series here. The remaining 4 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

AbbVie Inc. · ABBV

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+4.0 pp

Dec 2022+1.4 pp

Mar 2023−0.4 pp

Jun 2023−1.7 pp

Sep 2023−2.0 pp

Dec 2023−2.0 pp

Mar 2024−3.0 pp

Jun 2024−1.7 pp

Sep 2024−2.1 pp

Dec 2024−0.1 pp

Mar 2025+1.9 pp

Jun 2025+2.0 pp

Sep 2025+4.6 pp

Dec 2025+5.2 pp

Mar 2026+5.1 pp

Jun 2026+5.1 pp

Amgen Inc. · AMGN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+1.6 pp

Dec 20220.0 pp

Mar 2023−8.7 pp

Jun 2023−7.1 pp

Sep 2023−7.7 pp

Dec 2023−6.7 pp

Mar 2024+0.8 pp

Jun 2024+0.5 pp

Sep 2024+2.6 pp

Dec 2024+1.6 pp

Mar 2025+2.5 pp

Jun 2025+2.3 pp

Sep 2025+1.9 pp

Dec 2025+3.8 pp

Mar 2026+2.6 pp

Jun 2026+2.4 pp

AstraZeneca PLC · AZN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+7.4 pp

Dec 2022+6.3 pp

Mar 2023+6.5 pp

Jun 2023+10.0 pp

Sep 2023+8.6 pp

Dec 2023+1.8 pp

Mar 2024+0.8 pp

Jun 2024−2.3 pp

Sep 2024−4.4 pp

Dec 2024+2.4 pp

Mar 2025+2.6 pp

Jun 2025+3.3 pp

Sep 2025+5.3 pp

Dec 2025−0.1 pp

Mar 2026+0.8 pp

Jun 2026−0.3 pp

Bristol-Myers Squibb Company · BMY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+0.7 pp

Dec 2022−0.4 pp

Mar 2023+0.3 pp

Jun 2023−0.3 pp

Sep 2023+0.1 pp

Dec 2023−0.2 pp

Mar 2024−18.4 pp

Jun 2024−0.1 pp

Sep 2024+0.2 pp

Dec 2024−1.1 pp

Mar 2025+20.1 pp

Jun 2025+1.1 pp

Sep 2025+1.5 pp

Dec 2025+1.4 pp

Mar 2026+0.1 pp

Jun 2026+2.6 pp

Eli Lilly and Company · LLY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+4.1 pp

Dec 2022+2.2 pp

Mar 2023−6.7 pp

Jun 2023−5.4 pp

Sep 2023−0.6 pp

Dec 2023+2.7 pp

Mar 2024+5.3 pp

Jun 2024+7.9 pp

Sep 2024+1.9 pp

Dec 2024+4.5 pp

Mar 2025+7.1 pp

Jun 2025+4.9 pp

Sep 2025+5.8 pp

Dec 2025+4.3 pp

Mar 2026+9.4 pp

Jun 2026+5.8 pp

Gilead Sciences, Inc. · GILD

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−1.0 pp

Dec 2022−0.1 pp

Mar 2023−1.9 pp

Jun 2023−1.9 pp

Sep 2023−3.8 pp

Dec 2023−2.8 pp

Mar 2024+1.9 pp

Jun 2024+3.7 pp

Sep 2024+6.8 pp

Dec 2024+4.4 pp

Mar 2025+3.0 pp

Jun 2025+0.9 pp

Sep 2025−0.4 pp

Dec 2025+2.3 pp

Mar 2026+0.8 pp

Jun 2026+6.1 pp

GSK plc · GSK

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+0.1 pp

Dec 2022+3.1 pp

Mar 2023+0.3 pp

Jun 2023+2.8 pp

Sep 2023+2.5 pp

Dec 2023−2.5 pp

Mar 2024−0.1 pp

Jun 2024−0.4 pp

Sep 2024−4.5 pp

Dec 2024+0.3 pp

Mar 2025+1.7 pp

Jun 2025+0.9 pp

Sep 2025+6.3 pp

Dec 2025+1.0 pp

Mar 2026+0.1 pp

Jun 2026−4.1 pp

Johnson & Johnson · JNJ

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022−4.6 pp

Mar 2023—

Jun 2023−9.6 pp

Sep 2023—

Dec 2023+2.2 pp

Mar 2024—

Jun 2024+10.0 pp

Sep 2024+4.9 pp

Dec 2024+1.6 pp

Mar 2025−2.9 pp

Jun 2025−13.9 pp

Sep 2025−1.0 pp

Dec 2025+0.9 pp

Mar 2026+2.2 pp

Jun 2026+13.6 pp

Merck & Co., Inc. · MRK

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+3.7 pp

Dec 2022+5.0 pp

Mar 2023+1.7 pp

Jun 2023+1.9 pp

Sep 2023+2.1 pp

Dec 2023−3.8 pp

Mar 2024−1.1 pp

Jun 2024−3.9 pp

Sep 2024−6.5 pp

Dec 2024+8.5 pp

Mar 2025+5.6 pp

Jun 2025+5.5 pp

Sep 2025+7.9 pp

Dec 2025−6.2 pp

Mar 2026−3.7 pp

Jun 2026−8.6 pp

Novartis AG · NVS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−4.7 pp

Dec 2022−1.8 pp

Mar 2023−3.2 pp

Jun 2023—

Sep 2023+7.7 pp

Dec 2023+6.4 pp

Mar 2024+10.7 pp

Jun 2024+6.7 pp

Sep 2024+4.7 pp

Dec 2024+4.9 pp

Mar 2025+4.2 pp

Jun 2025+4.1 pp

Sep 2025+3.4 pp

Dec 2025−0.5 pp

Mar 2026−5.6 pp

Jun 2026−6.1 pp

Pfizer Inc. · PFE

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022+0.6 pp

Mar 2023—

Jun 2023−2.4 pp

Sep 2023−6.7 pp

Dec 2023−8.2 pp

Mar 2024—

Jun 2024−4.2 pp

Sep 2024+1.2 pp

Dec 2024+2.0 pp

Mar 2025−0.4 pp

Jun 2025+1.9 pp

Sep 2025−0.7 pp

Dec 2025−1.0 pp

Mar 2026+0.2 pp

Jun 2026−2.2 pp

Sanofi · SNY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−0.4 pp

Dec 2022+2.6 pp

Mar 2023−0.4 pp

Jun 2023+0.4 pp

Sep 2023+0.3 pp

Dec 2023−3.8 pp

Mar 2024−0.9 pp

Jun 2024−0.3 pp

Sep 2024+0.4 pp

Dec 2024+0.6 pp

Mar 2025+1.1 pp

Jun 2025−0.1 pp

Sep 2025+0.2 pp

Dec 2025−1.9 pp

Mar 2026−0.2 pp

Jun 2026−0.4 pp

09 · compare level, then change

Valuation Against Growth & Quality

Organon & Co. has the lowest PEG among the 16 Drug Manufacturers - General companies compared here, at 0.17×. Biogen Inc. is next at 0.38×. The same company also holds the lowest P/E, at 6.44×. 10 of 16 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Organon & Co. has the lowest comparable PEG at 0.17×, 55.3% below Biogen Inc.. Only 10 of 16 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

LeaderOrganon & Co. · 0.17×

Gap55.3% versus #2 · Biogen Inc.

Persistence0/8 recent comparable periods

Coverage10/16 companies · 47 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

PEGlowest PEG

1Organon & Co. OGN0.2

2Biogen Inc. BIIB0.4

3GSK plc GSK0.4

4Bristol-Myers Squibb Company BMY0.5

5Sanofi SNY0.6

P/Elowest P/E

1Organon & Co. OGN6.4

2Grifols, S.A. GRFS7.5

3Bristol-Myers Squibb Company BMY12.7

4Merck & Co., Inc. MRK14.3

5GSK plc GSK16.8

Valuation · company comparison

10/16 level · 16/16 change

All-company data · latest reported quarter

Company	PEG	P/E	Reported
Eli Lilly and Company LLY	8.6	40.0	Jun 2026
Novartis AG NVS	2.3	22.5	Jun 2026
Merck & Co., Inc. MRK	1.8	14.3	Jun 2026
AstraZeneca PLC AZN	1.1	27.8	Jun 2026
Amgen Inc. AMGN	0.7	22.4	Jun 2026
Grifols, S.A. GRFS	0.7	7.5	Jun 2026
Sanofi SNY	0.6	22.9	Jun 2026
Bristol-Myers Squibb Company BMY	0.5	12.7	Jun 2026
GSK plc GSK	0.4	16.8	Jun 2026
Biogen Inc. BIIB	0.4	38.2	Jun 2026
Gilead Sciences, Inc. GILD	0.3	18.8	Jun 2026
Organon & Co. OGN	0.2	6.4	Mar 2026
Johnson & Johnson JNJ	—	29.1	Jun 2026
AbbVie Inc. ABBV	—	70.9	Jun 2026
Pfizer Inc. PFE	—	32.0	Jun 2026
Amarin Corporation plc AMRN	—	168.5	Mar 2026

Full 20-quarter history · every available company

PEG · reported quarter history

Amgen Inc. · AMGN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 20230.4

Jun 20230.6

Sep 20231.5

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 20250.5

Jun 2025—

Sep 2025—

Dec 2025—

Mar 20260.8

Jun 20260.7

AstraZeneca PLC · AZN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 20241.0

Jun 2024—

Sep 20243.9

Dec 20241.6

Mar 20251.3

Jun 20250.9

Sep 20250.6

Dec 20250.6

Mar 20260.9

Jun 20261.1

Biogen Inc. · BIIB

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 20230.5

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 20241.7

Dec 20240.3

Mar 20250.5

Jun 20250.4

Sep 2025—

Dec 2025—

Mar 2026—

Jun 2026—

Bristol-Myers Squibb Company · BMY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 20230.9

Jun 20230.7

Sep 20230.5

Dec 20230.4

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 20260.5

Jun 2026—

Eli Lilly and Company · LLY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 20234.6

Sep 2023—

Dec 2023—

Mar 202414.4

Jun 20248.6

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Jun 2026—

Gilead Sciences, Inc. · GILD

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 20230.8

Jun 20230.5

Sep 2023—

Dec 20230.8

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 20260.3

Jun 2026—

Grifols, S.A. · GRFS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 20230.7

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Jun 2026—

GSK plc · GSK

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Jun 20260.4

Merck & Co., Inc. · MRK

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 20250.6

Sep 20250.2

Dec 20251.8

Mar 2026—

Jun 2026—

Novartis AG · NVS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 20250.9

Mar 20262.3

Jun 2026—

Organon & Co. · OGN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 20230.3

Mar 20240.1

Jun 20240.2

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Jun 2026—

Sanofi · SNY

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 20230.6

Jun 20230.5

Sep 20230.3

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 20250.5

Jun 2025—

Sep 2025—

Dec 2025—

Mar 20260.6

Jun 2026—

P/E · reported quarter history

Showing the 12 largest of 16 companies with a series here. The remaining 4 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

AbbVie Inc. · ABBV

Sep 202125.5

Dec 202120.9

Mar 202223.1

Jun 202221.5

Sep 202217.8

Dec 202224.3

Mar 202337.3

Jun 202327.5

Sep 202340.7

Dec 202356.8

Mar 202454.2

Jun 202457.2

Sep 202468.7

Dec 2024—

Mar 202589.2

Jun 202588.1

Sep 2025174.2

Dec 202596.5

Mar 2026107.0

Jun 202670.9

Amgen Inc. · AMGN

Sep 202121.5

Dec 202121.5

Mar 202223.5

Jun 202219.8

Sep 202217.6

Dec 202221.4

Mar 202316.3

Jun 202314.9

Sep 202319.0

Dec 202323.0

Mar 2024—

Jun 202453.6

Sep 202440.9

Dec 202434.3

Mar 202528.2

Jun 202522.7

Sep 202521.7

Dec 202522.9

Mar 202624.3

Jun 202622.4

AstraZeneca PLC · AZN

Sep 2021—

Dec 2021—

Mar 2022-194.1

Jun 2022-162.3

Sep 202284.2

Dec 202263.7

Mar 202345.8

Jun 202336.0

Sep 202335.6

Dec 202335.1

Mar 202433.0

Jun 202437.6

Sep 202437.1

Dec 202428.9

Mar 202529.0

Jun 202525.9

Sep 202524.8

Dec 202528.2

Mar 202629.0

Jun 202627.8

Bristol-Myers Squibb Company · BMY

Sep 2021—

Dec 202120.0

Mar 202225.9

Jun 202225.6

Sep 202223.2

Dec 202224.4

Mar 202320.2

Jun 202317.0

Sep 202314.7

Dec 202313.3

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 202522.8

Jun 202518.7

Sep 202515.2

Dec 202515.6

Mar 202617.0

Jun 202612.7

Eli Lilly and Company · LLY

Sep 202135.1

Dec 202144.9

Mar 202242.2

Jun 202251.3

Sep 202250.9

Dec 202255.7

Mar 202354.5

Jun 202368.5

Sep 2023—

Dec 2023100.0

Mar 2024114.2

Jun 2024111.0

Sep 202495.3

Dec 202465.6

Mar 202566.8

Jun 202550.7

Sep 202537.2

Dec 202546.6

Mar 202632.6

Jun 202640.0

Gilead Sciences, Inc. · GILD

Sep 202111.9

Dec 202114.6

Mar 202216.5

Jun 202218.7

Sep 202223.2

Dec 202223.5

Mar 202318.6

Jun 202317.5

Sep 202315.9

Dec 202317.8

Mar 2024—

Jun 202481.2

Sep 2024828.4

Dec 2024239.8

Mar 202523.4

Jun 202521.9

Sep 202517.0

Dec 202517.9

Mar 202618.8

Jun 2026—

GSK plc · GSK

Sep 202113.3

Dec 202115.1

Mar 202213.1

Jun 202215.9

Sep 20223.9

Dec 20224.0

Mar 20234.2

Jun 20233.9

Sep 202310.0

Dec 202312.1

Mar 202415.6

Jun 202415.5

Sep 202425.1

Dec 202421.7

Mar 202519.6

Jun 202516.9

Sep 202512.0

Dec 202513.1

Mar 202614.6

Jun 202616.8

Johnson & Johnson · JNJ

Sep 2021—

Dec 202123.6

Mar 202221.6

Jun 202223.6

Sep 2022—

Dec 202230.0

Mar 2023—

Jun 2023—

Sep 202345.1

Dec 202313.0

Mar 20249.9

Jun 20249.3

Sep 202426.5

Dec 202424.8

Mar 202518.1

Jun 202516.2

Sep 202517.2

Dec 202518.7

Mar 202627.5

Jun 202629.1

Merck & Co., Inc. · MRK

Sep 202126.4

Dec 202114.8

Mar 202214.6

Jun 202213.9

Sep 202214.3

Dec 202219.4

Mar 202320.7

Jun 2023—

Sep 202356.7

Dec 2023—

Mar 2024144.9

Jun 202422.8

Sep 202423.7

Dec 202414.7

Mar 202513.0

Jun 202512.1

Sep 202511.0

Dec 202514.3

Mar 2026—

Jun 2026—

Novartis AG · NVS

Sep 202118.8

Dec 20218.2

Mar 20228.2

Jun 2022—

Sep 20228.4

Dec 202237.0

Mar 202339.2

Jun 202327.6

Sep 202327.1

Dec 202314.0

Mar 202413.9

Jun 202413.5

Sep 202413.2

Dec 202416.4

Mar 202516.3

Jun 202517.4

Sep 202516.9

Dec 202519.0

Mar 202621.2

Jun 202622.5

Pfizer Inc. · PFE

Sep 2021—

Dec 202112.4

Mar 2022—

Jun 202211.7

Sep 202210.2

Dec 20228.4

Mar 2023—

Jun 20238.0

Sep 20239.8

Dec 202318.1

Mar 2024—

Jun 2024—

Sep 202439.3

Dec 202418.8

Mar 202518.3

Jun 202512.9

Sep 202513.8

Dec 202518.3

Mar 202620.6

Jun 202632.0

Sanofi · SNY

Sep 202116.9

Dec 202117.8

Mar 202217.4

Jun 202218.0

Sep 202215.2

Dec 202213.6

Mar 202315.0

Jun 202314.3

Sep 202314.0

Dec 202320.9

Mar 202424.8

Jun 202426.9

Sep 202428.7

Dec 202420.9

Mar 202520.3

Jun 202511.1

Sep 202510.8

Dec 202513.0

Mar 202613.4

Jun 202622.9

10 · before the conclusion, check the blind spots

What can make this comparison misleading?

This Drug Manufacturers - General comparison names 4 specific ways its own evidence can mislead, all listed below. All 16 companies here report on comparable dates, so no rank carries a stale marker. A high growth rate can still be a low-base artefact.

Keep these limits visible

A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.

11 · evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 16 Drug Manufacturers - General companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-09-16. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.

FundamentalsThrough Jun 2026 · up to 20 quarters per company

Market dataThrough 2026-09-16 · weekly price and relative-strength history

Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.

Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.

12 · questions investors ask, short speakable answers

Drug Manufacturers - General company comparison FAQs

These 22 answers restate the Drug Manufacturers - General comparison above in question form. Every one is computed from the same 16 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-09-16. Nothing here is estimated, and none of it is a recommendation.

Is the Drug Manufacturers - General sector outperforming S&P 500?

Which Drug Manufacturers - General company is largest by revenue?

Johnson & Johnson leads with revenue of $97,929 million, based on 15 of 16 comparable companies through Jun 2026.

Which Drug Manufacturers - General company is growing fastest?

Eli Lilly and Company has the fastest current revenue growth at 49.6%, across 15 of 16 comparable companies.

Which Drug Manufacturers - General company has the strongest 4-Factor Sector Score?

AbbVie Inc. ranks first at 75.2/100 with 75.3% evidence confidence. The score prioritizes research; it is not a buy recommendation.

Which Drug Manufacturers - General company has the lowest comparable PEG?

Organon & Co. has the lowest comparable PEG at 0.17, among 10 of 16 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Drug Manufacturers - General comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

Which Drug Manufacturers - General company is the biggest?

Johnson & Johnson is the largest, with trailing-twelve-month revenue of $97,929 million, ahead of Eli Lilly and Company at $79,666 million. That covers 15 of 16 companies with comparable reporting through Jun 2026.

Which Drug Manufacturers - General company has the best profit margins?

Eli Lilly and Company has the highest operating margin at 54.2%, from 16 of 16 comparable companies. Amarin Corporation plc shows the biggest recent improvement, at +14.8 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Drug Manufacturers - General company makes the most profit?

Eli Lilly and Company earns the most, at $26,712 million of trailing-twelve-month net profit, from 15 of 16 comparable companies. Eli Lilly and Company has the fastest profit growth at 93.6%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Drug Manufacturers - General company earns the highest return on capital?

Eli Lilly and Company leads on return on capital employed at 41.7%, across 16 of 16 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Which Drug Manufacturers - General stock is the cheapest?

On PEG — where a LOWER number is cheaper — Organon & Co. screens cheapest at 0.17×. Only 10 of 16 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

Is the Drug Manufacturers - General sector beating the market?

Drug Manufacturers - General has outperformed S&P 500 by 8% over the last 52 weeks and 5.4% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 9 of 16 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Drug Manufacturers - General stock has the strongest price momentum?

Organon & Co. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Drug Manufacturers - General company scores highest for research priority?

AbbVie Inc. scores 75.2 out of 100 with 75.3% evidence confidence, from 28.8 points on growth and earnings, 20.1 on capital efficiency, 8.7 on valuation and 17.6 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Drug Manufacturers - General companies does this comparison cover, and over what period?

It compares 16 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Drug Manufacturers - General sector?

The 16 Drug Manufacturers - General companies on this page carry $3,916,762 million of combined market value. Eli Lilly and Company is the largest at $1,014,204 million, about 26% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-09-16.

What is the Drug Manufacturers - General sector's P/E ratio?

The median price-to-earnings ratio across the 16 Drug Manufacturers - General companies on this page is 22.9×, measured on the 16 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-09-16.

How is the Drug Manufacturers - General sector performing?

9 of the 16 covered Drug Manufacturers - General companies are beating S&P 500 on Mansfield relative strength. The sector itself is 8% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-09-16.

How many Drug Manufacturers - General stocks are listed in the US?

This comparison covers 16 listed Drug Manufacturers - General companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Jun 2026. Membership is the full industry list — nothing is dropped for having thin data.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.

About

Not SEBI Registered !! Not Investment advice !!